Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Lauterbach

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
The European Respiratory Journal|January 11, 2005
Asthma: prevalence and cost of illnessS Stock, M Redaelli, M Luengen, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|February 24, 2006
Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in GermanyS A K Stock, M Redaelli, G Wendland, et al.
The American Journal of Geriatric Pharmacotherapy|November 26, 2008
Quantification and classification of errors associated with hand-repackaging of medications in long-term care facilities in GermanyAndreas Gerber, Ines Kohaupt, Karl W Lauterbach, et al.
Nuklearmedizin. Nuclear Medicine|February 13, 1999
[Cost-effectiveness analysis: radioiodine or antithyroid medication in primary treatment of immune hyperthyroidism]M Dietlein, D Moka, B Dederichs, et al.
Journal of Women'S Health (2002)|March 15, 2008
Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insuranceStephanie A K Stock, Björn Stollenwerk, Marcus Redaelli, et al.
Nuklearmedizin. Nuclear Medicine|February 19, 1998
[Consequences of new patient discharge guidelines on the cost structure of radioiodine therapy]M Dietlein, C J Troche, D Moka, et al.
Medizinische Klinik (Munich, Germany : 1983)|February 27, 2009
[Does the lack of evidence of effectiveness among international studies on interventions in prevention and health promotion have an impact on a German Act of Prevention?]Markus Lüngen, Milly-Anna Schröer-Günther, Anna Marie Passon, et al.
European Journal of Nuclear Medicine|November 18, 2000
Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in GermanyM Dietlein, K Weber, A Gandjour, et al.
European Journal of Nuclear Medicine|December 6, 2000
Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT resultsM Dietlein, K Weber, A Gandjour, et al.
Cerebrovascular Diseases (Basel, Switzerland)|December 25, 2002
Management patterns and health care use after intracerebral hemorrhage. a cost-of-illness study from a societal perspective in GermanyChristian Weimar, Carsten Weber, Markus Wagner, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
The European Respiratory Journal|January 11, 2005
Asthma: prevalence and cost of illnessS Stock, M Redaelli, M Luengen, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|February 24, 2006
Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in GermanyS A K Stock, M Redaelli, G Wendland, et al.
The American Journal of Geriatric Pharmacotherapy|November 26, 2008
Quantification and classification of errors associated with hand-repackaging of medications in long-term care facilities in GermanyAndreas Gerber, Ines Kohaupt, Karl W Lauterbach, et al.
Nuklearmedizin. Nuclear Medicine|February 13, 1999
[Cost-effectiveness analysis: radioiodine or antithyroid medication in primary treatment of immune hyperthyroidism]M Dietlein, D Moka, B Dederichs, et al.
Journal of Women'S Health (2002)|March 15, 2008
Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insuranceStephanie A K Stock, Björn Stollenwerk, Marcus Redaelli, et al.
Nuklearmedizin. Nuclear Medicine|February 19, 1998
[Consequences of new patient discharge guidelines on the cost structure of radioiodine therapy]M Dietlein, C J Troche, D Moka, et al.
Medizinische Klinik (Munich, Germany : 1983)|February 27, 2009
[Does the lack of evidence of effectiveness among international studies on interventions in prevention and health promotion have an impact on a German Act of Prevention?]Markus Lüngen, Milly-Anna Schröer-Günther, Anna Marie Passon, et al.
European Journal of Nuclear Medicine|November 18, 2000
Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in GermanyM Dietlein, K Weber, A Gandjour, et al.
European Journal of Nuclear Medicine|December 6, 2000
Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT resultsM Dietlein, K Weber, A Gandjour, et al.
Cerebrovascular Diseases (Basel, Switzerland)|December 25, 2002
Management patterns and health care use after intracerebral hemorrhage. a cost-of-illness study from a societal perspective in GermanyChristian Weimar, Carsten Weber, Markus Wagner, et al.
Pageof 8